Tumor
Conditions
Keywords
tumor, biopsy, tru-cut, core-cut, cancer, pelvic tumor
Brief summary
Tru-cut biopsy (TCB) is a minimally invasive method to get an adequate sample from the lesion in order to tailor the appropriate management avoiding unnecessary surgery. The aim of our trial is to evaluate the adequacy, accuracy and safety of the method related to the final histology as reference standard.
Detailed description
The primary endpoint is represented by the assessment of adequacy, accuracy and safety of the procedure in prospective settings. The secondary endpoint is to evaluate feasibility of immunohistochemistry (IHC), next generation sequencing (NGS) and tumor immunology in obtained samples by TCB and to assess the alterations of these tumor characteristics in relation to the treatment. The additional endpoint includes the effect of several variables (e.g. tumor origin, size of the tumor, presence of ascites, body mass index (BMI), biopsy site, biopsy approach - transvaginal, transrectal vs. transabdominal, status of the disease - the first diagnosis, the first and other recurrence or progression and previous treatment modality - chemotherapy, anti-angiogenic therapy, PARP inhibitor therapy, hormonal therapy, radiotherapy) on the outcome of the procedure (adequacy, accuracy and safety). All patients indicated for tru-cut biopsy (including advanced stages of ovarian, endometrial or cervical cancers) in Gynecologic Oncology Center of the General University Hospital from February 2024 to January 2026 will be recruited. Furthermore, all patients with suspicious recurrence or progression of already known gynecologic malignancy based on the imaging methods will be recruited. The duration of recruitment is 3 years, and we expect 250 patients enrolled into the trial. Data will be assessed in relation to the patient characteristics, tumor/lesion characteristics, procedure specifications, histopathological characteristics and IHC/NGS/immunological characteristics, consequent biopsy/surgery and final histopathological results. All adverse events will be recorded. Moreover, patient related outcomes will be recorded within 72 hours after the procedure. This prospective study could support our hypothesis that TCB is feasible and safe procedure with high adequacy and accuracy rate. It enables to get appropriate outcomes of IHC, NGS and immunology preoperatively. We expect that TCB is applicable and efficient in majority of recurrences/disease progressions, so it can be considered suitable technique for de novo biopsy. It can help us show the alterations of tumor characteristics after the previous treatment and can be used to select appropriate targeted therapy.
Interventions
PROCEDUREtru-cut biopsy
needle biopsy from the tumor
Sponsors
General University Hospital, Prague
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Presence of a pelvic/abdominal lesion with suspicion of malignancy: 1. new diagnosis of a presumed gynecologic tumor 2. suspicious recurrence or progression of a known gynecologic malignancy 3. pelvic/abdominal spread or recurrence of a non-gynecologic tumor (primary tumor or metastasis) 4. pelvic/abdominal spread of a tumor of unknown origin 2. Age ≥18 years 3. Eastern Cooperative Oncology Group (ECOG) performance status grade \<3 4. Not pregnant 5. Signed informed consent form
Exclusion criteria
1. Considered by the investigator to be unsuitable for any treatment 2. Early stage disease 3. Age \<18 years
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The adequacy of samples obtained by TCB for histopathological examination (in %) | First data 31st of June 2025, definitive data 31st of January 2026 | 1\. The adequacy means the ability to determine the type of tumor (in %) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The adequacy of samples obtained by TCB for next-generation sequencing examination (in %) | First data 31st of June 2025, definitive data 31st of January 2026 | 2\. Adequacy of samples obtained by TCB for next-generation sequencing examination (in %) Adequacy is defined as the ability to determine the complex classification of the tumor. |
| The adequacy of samples obtained by TCB for immunohistochemistry examination (in %) | First data 31st of June 2025, definitive data 31st of January 2026 | 3\. Adequacy of samples obtained by TCB for immunohistochemistry examination (in %) Adequacy is defined as the ability to determine the complex classification of the tumor. |
| The adequacy of samples obtained by TCB for immunologic examination (in %) | First data 31st of June 2025, definitive data 31st of January 2026 | 4\. Adequacy of samples obtained by TCB for immunologic examination (in %) Adequacy is defined as the ability to determine the complex classification of the tumor. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Overall safety of TCB (in %) | First data 31st of June 2025, definitive data 31st of January 2026 | 6\. Overall safety of TCB (in %) |
| Overall accuracy of TCB for complex classification of pelvic and abdominal tumors (in %) | First data 31st of June 2025, definitive data 31st of January 2026 | 7\. Overall accuracy of TCB for complex classification of pelvic and abdominal tumors (in %) |
| 1. To evaluate which factors affect the primary and secondary endpoints 2. To evaluate the overall safety of TCB (in %) 3. To evaluate the overall accuracy of TCB for complex classification of pelvic and abdominal tumors (in %) | First data 31st of June 2025, definitive data 31st of January 2026 | 5\. Evaluation of factors affecting the primary and secondary endpoints Includes tumor origin, size, presence of ascites, BMI, biopsy site, biopsy approach, disease status, and previous treatment modalities. |
Countries
Czechia
Contacts
Primary ContactRenata Poncová, MD.
Backup ContactFilip Frühauf, MD.
Outcome results
None listed